UniProt P08581
Hepatocyte growth factor receptor (P08581)
Hepatocyte growth factor receptor (UniProt P08581), EC 2.7.10.1: 210 experimental structures and 1 predicted model on GenesisL1, 46 ligands bound, 172 pockets. Binding sites, druggability and experiment against prediction…
- UniProt
- P08581
- Protein
- Hepatocyte growth factor receptor
- EC
- 2.7.10.1
- Experimental structures
- 210
- Predicted models
- 1
- Ligands
- 46
- Pockets
- 172 · 38 records with a druggable one
Structures
211 records of P08581 in the MolNFT archive: 210 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1FYR | Dimer formation through domain swapping in the crystal structure of the GRB2-SH2 ac-pyvnv complex | x-ray diffraction | I, J, K, L | — | — |
| 1FYR | Dimer formation through domain swapping in the crystal structure of the GRB2-SH2 ac-pyvnv complex | x-ray diffraction | I, J, K, L | — | — |
| 1R0P | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met in… | x-ray diffraction | A | — | — |
| 1R0P | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-met in… | x-ray diffraction | A | — | — |
| 1R1W | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-met | x-ray diffraction | A | — | — |
| 1R1W | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-met | x-ray diffraction | A | — | — |
| 1SHY | The Crystal Structure of HGF beta-chain in Complex with the Sema Domain of the Met Receptor. | x-ray diffraction | B | — | — |
| 1SHY | The crystal structure of hgf beta-chain in complex with the sema domain of the met receptor. | x-ray diffraction | B | — | — |
| 1SSL | Solution structure of the PSI domain from the Met receptor | solution nmr | A | — | — |
| 1SSL | Solution structure of the psi domain from the met receptor | solution nmr | A | — | — |
| 2RFN | x-ray structure of c-Met with inhibitor. | x-ray diffraction | A, B | — | — |
| 2RFN | X-ray structure of C-met with inhibitor. | x-ray diffraction | A, B | — | — |
| 2RFS | X-ray structure of SU11274 bound to c-Met | x-ray diffraction | A | — | — |
| 2RFS | X-ray structure of SU11274 bound to C-met | x-ray diffraction | A | — | — |
| 2UZX | Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes… | x-ray diffraction | B, D | — | — |
| 2UZX | Structure of the human receptor tyrosine kinase met in complex with the listeria monocytogenes… | x-ray diffraction | B, D | — | — |
| 2UZY | Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes… | x-ray diffraction | B, D | — | — |
| 2UZY | Structure of the human receptor tyrosine kinase met in complex with the listeria monocytogenes… | x-ray diffraction | B, D | — | — |
| 2WD1 | Human c-Met Kinase in complex with azaindole inhibitor | x-ray diffraction | A | — | — |
| 2WD1 | Human C-met kinase in complex with azaindole inhibitor | x-ray diffraction | A | — | — |
| 2WGJ | X-ray Structure of PF-02341066 bound to the kinase domain of c-Met | x-ray diffraction | A | — | — |
| 2WGJ | X-ray structure of pf-02341066 bound to the kinase domain of C-met | x-ray diffraction | A | — | — |
| 2WKM | X-ray Structure of PHA-00665752 bound to the kinase domain of c-Met | x-ray diffraction | A | — | — |
| 2WKM | X-ray structure of pha-00665752 bound to the kinase domain of C-met | x-ray diffraction | A | — | — |
| 3A4P | human c-MET kinase domain complexed with 6-benzyloxyquinoline inhibitor | x-ray diffraction | A | — | — |
| 3A4P | Human C-met kinase domain complexed with 6-benzyloxyquinoline inhibitor | x-ray diffraction | A | — | — |
| 3BUX | Crystal structure of c-Cbl-TKB domain complexed with its binding motif in c-Met | x-ray diffraction | A, C | — | — |
| 3BUX | Crystal structure of C-cbl-tkb domain complexed with its binding motif in C-met | x-ray diffraction | A, C | — | — |
| 3C1X | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET in… | x-ray diffraction | A | — | — |
| 3C1X | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-met in… | x-ray diffraction | A | — | — |
| 3CCN | X-ray structure of c-Met with triazolopyridazine inhibitor. | x-ray diffraction | A | — | — |
| 3CCN | X-ray structure of C-met with triazolopyridazine inhibitor. | x-ray diffraction | A | — | — |
| 3CD8 | X-ray Structure of c-Met with triazolopyridazine Inhibitor. | x-ray diffraction | A | — | — |
| 3CD8 | X-ray structure of C-met with triazolopyridazine inhibitor. | x-ray diffraction | A | — | — |
| 3CE3 | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in… | x-ray diffraction | A | — | — |
| 3CE3 | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-met in… | x-ray diffraction | A | — | — |
| 3CTH | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in… | x-ray diffraction | A | — | — |
| 3CTH | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-met in… | x-ray diffraction | A | — | — |
| 3CTJ | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in… | x-ray diffraction | A | — | — |
| 3CTJ | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-met in… | x-ray diffraction | A | — | — |
| 3DKC | Structure of MET receptor tyrosine kinase in complex with ATP | x-ray diffraction | A | — | — |
| 3DKC | Structure of met receptor tyrosine kinase in complex with ATP | x-ray diffraction | A | — | — |
| 3DKF | Structure of MET receptor tyrosine kinase in complex with inhibitor SGX-523 | x-ray diffraction | A | — | — |
| 3DKF | Structure of met receptor tyrosine kinase in complex with inhibitor sgx-523 | x-ray diffraction | A | — | — |
| 3DKG | Structure of Mutant(Y1248L) MET receptor tyrosine kinase in complex with inhibitor SGX-523 | x-ray diffraction | A | — | — |
| 3DKG | Structure of MUTANT(Y1248L) met receptor tyrosine kinase in complex with inhibitor sgx-523 | x-ray diffraction | A | — | — |
| 3EFJ | Structure of c-Met with pyrimidone inhibitor 7 | x-ray diffraction | A, B | — | — |
| 3EFJ | Structure of C-met with pyrimidone inhibitor 7 | x-ray diffraction | A, B | — | — |
| 3EFK | Structure of c-Met with pyrimidone inhibitor 50 | x-ray diffraction | A, B | — | — |
| 3EFK | Structure of C-met with pyrimidone inhibitor 50 | x-ray diffraction | A, B | — | — |
| 3F66 | Human c-Met Kinase in complex with quinoxaline inhibitor | x-ray diffraction | A, B | — | — |
| 3F66 | Human C-met kinase in complex with quinoxaline inhibitor | x-ray diffraction | A, B | — | — |
| 3F82 | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in… | x-ray diffraction | A | — | — |
| 3F82 | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-met in… | x-ray diffraction | A | — | — |
| 3I5N | Crystal structure of c-Met with triazolopyridazine inhibitor 13 | x-ray diffraction | A | — | — |
| 3I5N | Crystal structure of C-met with triazolopyridazine inhibitor 13 | x-ray diffraction | A | — | — |
| 3L8V | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in… | x-ray diffraction | A | — | — |
| 3L8V | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-met in… | x-ray diffraction | A | — | — |
| 3LQ8 | Structure of the kinase domain of c-Met bound to XL880 (GSK1363089) | x-ray diffraction | A | — | — |
| 3LQ8 | Structure of the kinase domain of C-met bound to XL880 (GSK1363089) | x-ray diffraction | A | — | — |
151 records more on the page itself.
Ligands
- CL · Chloride ion · in 12 records
- SO4 · Sulfate ion · in 7 records
- NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · in 4 records
- 3E8 · 3-[1-(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}benzyl)-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile · in 3 records
- 63K · 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-[2-(morpholin-4-yl)ethyl]urea · in 3 records
- 88Z · N-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide · in 3 records
- MDI · 3-[bis(fluoranyl)methyl]-~{N}-methyl-~{N}-[(1~{R})-8-methyl-5-(3-methyl-1~{H}-indazol-6-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]pyridine-2-carboxamide · in 3 records
- 353 · N-{4-[(2-amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl}-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide · in 2 records
- 5I9 · ~{N}1'-[3-fluoranyl-4-(10~{H}-pyrido[3,2-B][1, 4]benzoxazin-4-yloxy)phenyl]-~{N}1-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide · in 2 records
- 5IE · ~{N}1'-[3-fluoranyl-4-(2-phenylazanylpyrimidin-4-yl) oxy-phenyl]-~{N}1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide · in 2 records
- 6TD · 2-[3-(4-methoxybenzyl)[1,2,4]triazolo[3,4-B][1,3, 4]thiadiazol-6-yl]-1H-indole · in 2 records
- 75H · N-{3-fluoro-4-[(7-methoxyquinolin-4-yl)oxy]phenyl}-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenyl-2, 3-dihydro-1H-pyrazole-4-carboxamide · in 2 records
- 84M · N-{6-[([1,2,4]triazolo[4,3-a]pyridin-3-yl) sulfanyl]imidazo[1,2-b]pyridazin-2-yl}cyclopropanecarboxamide · in 2 records
- 84P · N-(6-{[6-(1-methyl-1H-pyrazol-4-yl)-1H-benzotriazol-1-yl]methyl}imidazo[1,2-b]pyridazin-2-yl) cyclopropanecarboxamide · in 2 records
- 84S · N-(6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2, 4]triazolo[4,3-a]pyridin-3-yl]methyl}imidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxamide · in 2 records
- FUC · alpha-L-fucopyranose · in 2 records
- SV5 · 1-(phenylmethyl)-5~{H}-pyrrolo[3,2-c]pyridin-4-one · in 2 records
- SVH · 3-(6-fluoranyl-1~{H}-indazol-4-yl)-4,5-dihydro-1~{H}-pyrrolo[3,4-b]pyrrol-6-one · in 2 records
- SVT · 5-methoxy-1~{H}-indazole · in 2 records
- SWB · 3-(3-methyl-1~{H}-pyrrolo[2,3-b]pyridin-5-yl)-1~{H}-pyrrolo[3,4-b]pyrrol-6-one · in 2 records
- V0L · volitinib · in 2 records
- 44X · 6-{(1S)-1-[8-fluoro-6-(3-methyl-1,2-oxazol-5-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)quinoline · in 1 record
- 5B4 · N-(2,5-difluoro-4-{[2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxam ide · in 1 record
- 5QQ · 6-[bis(fluoranyl)-[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl]methyl]quinoline · in 1 record
- 5SZ · 6-[(1~{R})-1-[8-fluoranyl-6-(3-methyl-1,2-oxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-1,6-naphthyridin-5-one · in 1 record
- 5T1 · 6-[(1~{R})-1-[8-fluoranyl-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one · in 1 record
- 62E · 1-[2-(1-ethylpiperidin-4-yl)ethyl]-3-(6-{[6-(thiophen-2-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)urea · in 1 record
- 63B · methyl (6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1H-benzimidazol-2-yl)carbamate · in 1 record
- 66L · N-[3-fluoro-4-({7-[2-(morpholin-4-yl)ethoxy]-1,6-naphthyridin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide · in 1 record
- A1ATS · N-(2,5-difluoro-4-{[(1s,3S)-3-(1-methyl-1H-pyrazol-3-yl)cyclobutyl][(8R)-pyrazolo[1,5-a]pyrazin-4-yl]amino}phenyl)-2-(5-fluoropyridin-2-yl)-3-oxo-2,3-dihydropyridazine-4-carboxamide · in 1 record
Experiment against prediction
- 6I04 chain B against the predicted model P08581: TM-score 0.99, RMSD 0.94 Å
- 4O3T chain B against the predicted model P08581: TM-score 0.98, RMSD 1.07 Å
- 1FYR chain I against the predicted model P08581: TM-score 0.98, RMSD 0.07 Å
- 1FYR chain I against the predicted model P08581: TM-score 0.98, RMSD 0.07 Å
- 6I04 chain A against the predicted model P08581: TM-score 0.98, RMSD 1.29 Å
- 7MOB chain D against the predicted model P08581: TM-score 0.97, RMSD 1.42 Å
- 7MOB chain C against the predicted model P08581: TM-score 0.97, RMSD 1.42 Å
- 5LSP chain A against the predicted model P08581: TM-score 0.97, RMSD 1.01 Å
- 6GCU chain D against the predicted model P08581: TM-score 0.96, RMSD 1.85 Å
- 6GCU chain A against the predicted model P08581: TM-score 0.96, RMSD 1.95 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.